Primary Source Monitoring: Eli Lilly and Company v. Lone Star Peptide Co. LLC (4:26-cv-06562) — District Court, S.D. Texas
Eli Lilly's lawsuit may impact peptide supply chains for med spas.
What changed & why it matters
MedSpaRadar recorded a regulatory change at the federal level, dated August 12, 2026, in the Peptides category.
This change is tracked for its potential impact on med-spa and injectable practice — what a practice may do, who may perform it, and from whom product may be sourced.
- Type
- Primary Source Monitoring
- Jurisdiction
- Federal
- Category
- Peptides
- Recorded
- August 12, 2026
What this means for your practice — the step to take, the deadline to calendar or the supplier detail to check, where the change calls for one — is in the member "what to do" below. This page is the free record of what changed and why it matters.
What to do
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get a specific “what to do” wherever a change calls for one — in one daily email, for your states. See one unlocked → · Pricing →
Primary Source Monitoring · primary source ↗
Related alerts
MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director.